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TETRACYCLINES IN SWINE WASTE 
Natalie Jones  May 2014 Pages 48 
Directed by: Dr. Eric Conte, Dr. John Loughrin, Dr. Stuart Burris 
Department of Chemistry Western Kentucky University  
Antibiotics are added to animal feeds as prophylactic agents and to encourage 
weight gain in livestock. However, there is concern that the widespread use of antibiotics 
in animal agriculture encourages for the selection of resistance genes and has contributed 
to the rise of multiply antibiotic resistant strains of pathogenic bacteria. For this reason, 
there is interest in quantifying antibiotics in environmental samples. The determination of 
three antibiotics in swine waste, namely chlortetracycline, tetracycline and 
oxytetracycline, using LC-MS with electrospray ionization is presented here in. 
Antibiotics from swine waste were quantified across the lifespan of the swine. Trends 
were present in each of the four life stages (gestation, farrowing, nursery, and finishing). 
The nursery stage of life presented the most dominate concentrations and the most 
consistent trend in antibiotic concentrations. 
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I. INTRODUCTION 
A. Background 
One of the growing topics in veterinary medicine is the use of antibiotics in 
livestock feeds, which have environmental impacts caused by the use of the waste as 
fertilizer on fields in which crops are grown and ground water run-off.  These antibiotics 
are the center of a growing controversy over the widespread use of antibiotics creating 
dangerous antibiotic-resistant bacteria.  This thesis deals with swine production and the 
affects antibiotics have on swine by utilizing research that has been conducted with solid 
phase extraction and liquid chromatography mass spectroscopy (LCMS) methods. 
Antibiotic means “against life” or “destructive to life”.1 A more extensive 
definition of antibiotic is a substance produced by, or derived from, a living organism.1  
Most antibiotics that are being used in medicinal treatment are produced from various 
bacteria or mold, some microorganisms even produce their own antibiotics that will kill 
other organisms.  Antibiotics can be further classified by the way they interact with the 
organism they are trying to kill.  These types of antibiotics along with their characteristics 
are shown in table 1. It should be noted that each of these antibiotic categories can be 
broken down again into more specific variations.  For example, chlortetracycline is a 
form of a tetracycline. 
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Table 1. Types of antibiotics and their characteristics1 
Antibiotic Characteristics of Antibiotic 
Penicilin and Bacitracin Agents that act of the cell wall on the 
bacteria. 
Polymyxin and Novobiocin Agents that have degenerate effects on the 
cell membrane. 
Tetracyclines and Streptomycin Agents that interfere with protein 
synthesis. 
Griseofulvin Agents that affect nucleic acid and 
metabolism. 
 
 It is estimated that in the United States over 24.6 million pounds of antibiotics are 
used for nontherapeutic purposes or without a known infection present.2  Antibiotics can 
be administered to the animal in several different forms either by injection or by 
feed/water additive.  The most common type of introduction is through the addition of 
antibiotics to feedstocks.  There are at least eleven antibacterial or antifungal compounds 
widely used as feed additives swine. These compounds are various salts of bacitracin, 
chlortetracycline, dynafac, mycostatin, oxytetracycline, oleandomycin, penicillin, 
streptomycin, bambermycins, tilmicosin, and tylosin.1 The three classifications of 
antibiotics that are the most common and  the most risk for overlapping between human 
and livestock are tetracycline, erythromycin, and penicillin.  
These antibiotics are typically added to feed for the purpose of greater and faster 
growth of the animal.  Specifically in swine, antibiotics mainly alter the microbial 
population of the intestinal tract.  The antibiotics can affect the swine in three ways: 
enhancing the growth of intestinal organisms that synthesize the nutrients required in an 
animal, depressing the growth of organisms that compete with the host organism for 
nutrients, and reducing the intestinal wall thickness, potentially improving the intestinal 
absorption of nutrients. 
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With a solid understanding of what antibiotics are and how they are introduced to 
swine, it is easier to understand how they can be detrimental to humans. The main 
concern about antibiotics being used in excess in swine production is the increasing 
abundance of antibiotic resistance and the transfer of resistance to pathogens.3 The 
antibiotics that are being used in the production of swine are suspected to be producing 
antibiotic-resistant bacteria that are being excreted from the animals in their waste. This 
waste is then spread on fields as fertilizer and can contaminate run off water.  There have 
been countless studies reviewing this issue. The Food and Drug administration (FDA) 
and other government agencies are currently responding to these concerns. 
The Government Accounting Office (GAO) stated in the April 1999 report, “The 
Agricultural Use of Antibiotics and Its Implications for Human Health,” that  
“in light of the emergence of antibiotic resistance in humans, questions about the 
extent that the agricultural use of antibiotics contributes to the human health burden, and 
the debate over whether further regulation or restriction of use in agriculture is needed, 
we recommend that the Secretaries of Agriculture and of Health and Human Services 
develop and implement a plan that contains specific goals, time frames, and resources 
needed to evaluate the risks and benefits of the existing and future use of antibiotics in 
agriculture, including identifying and filling critical data gaps and research needs.”4  
This was the first step a government agency had in the influence of what 
antibiotics were to be used in livestock feed and how they were to be regulated.  
“However, the House and Senate committees on Appropriations agreed with the 
GAO and immediately stated that they wanted to conduct a risk assessment of the human 
health risk linked to on-farm antimicrobial use. The House committee took it a step 
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further and decided they would also like to direct a report comparing the risk of 
resistance in foodborne pathogens from the on-farm use of antimicrobials with that of the 
other uses of antimicrobials.”4  
The interest in the new concern grew, and continued to grow, eventually getting 
several different agencies involved. 
In 1999 the Council of Food and Safety began to look at this issue in more broad 
terms. The concern was no longer just food safety but all aspects of resistance as a public 
health program. These broader approaches lead to the publication of “Draft Public Health 
Action Plan to Combat Antimicrobial Resistance,”4 which was a framework for goals to 
be achieved within several years. The Draft assessed agricultural antimicrobial use and 
examined the problem of resistance as a food safety issue. With the broader definition of 
the assessment, specific agencies took on different sides of the issues.  An example of 
this is the Center for Veterinary Medicine taking over the responsibility of health risks 
that are posed by the use of antimicrobial drugs in livestock production. They would look 
specifically into the pathogen/drug/outcome combinations using data that came from the 
research. 
B. Government Recommendations 
The Draft Action Plan4 proposed goals of how to determine if the antibiotics 
being used in livestock production can be harmful to human beings. The first division of 
the goals was under the Surveillance tab. The main goal that was presented in this section 
was to develop and implement procedures for monitoring patterns of antimicrobial drug 
use in human medicine, agriculture and consumer products. The next section was 
Prevention and Control; the goals for this section were to develop and implement a public 
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education campaign to promote judicious antimicrobial use as a national health priority. 
There were two other suggestions in this division. The first was to disseminate and 
evaluate clinical guidelines that address judicious antimicrobial use. The next suggestion 
was to refine and implement the new proposed framework by the FDA. This framework 
is for new antimicrobial drugs that are used in livestock production. In the Research 
Section there are two recommendations for improvement. The first recommendation is to 
provide all technologies required to identify the emerging resistant pathogens. The 
second of these recommendations is to develop and test rapid diagnostic methods. The 
last section with recommendations is product development; this section has two 
recommendations. The first of these is to create a product development working group 
whose purpose is to promote the priority of public health needs. The second 
recommendation was to be able to talk to the different communities about the products 
that can be helpful in the markets that purchasing incentives are not working well”4  
The FDA released an article by the title Framework Document5; this document 
addresses increasing resistance to antimicrobial drug treatment in bacteria that infect 
humans. These findings  raised the question of how the use of antimicrobial drugs in 
livestock production plays a role in the drug resistance of bacteria. The FDA places 
blame not only on the use of antibiotics in livestock production but also on the overuse of 
antibiotics in human treatment. However, this article expresses the concerns with the 
animal production side of the issue.   
“FDA is charged with the regulatory responsibility of ensuring that the use of 
antimicrobial drugs in food-producing animals does not result in adverse health 
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consequences to humans. Although this is the main charge and responsibility of the FDA 
they also understand that antibiotics are essential for the growth of livestock.”5 
 The need is to have enough antibiotics in the feed for proper growth, but also not 
to be so abundant in antibiotics that it is harmful to the animal and humans; they are 
looking for a balance between the two. 
The FDA released that they needed to evaluate two things in particular. First is 
the amount of antimicrobial drug resistant bacteria that are present in livestock intestinal 
track after the animal is exposed to a new antimicrobial drug. The second is the amount 
of bacteria in the animal’s intestines that is considered harmful to humans.  When an 
antimicrobial antibiotic is used, the bacteria that are the most sensitive to the drug are 
inhibited. These bacteria can then mutate or acquire the ability to be able to resist the 
antimicrobial drug; this can be especially detrimental to humans if the bacteria are 
disease-causing. A bacterial strain that is antibiotic resistant in livestock has the potential 
to be resistant in humans.  It is also possible that bacteria that is not pathogenic to 
animals, is pathogenic to humans, is passed on by eating the animal.  Three very good 
examples of how this can occur are Salmonella, Campylobacter, and E. coli O157. All 
three of these can be found in animal products and are not be pathogenic to the animal; 
however, they are pathogenic to humans.  It is very well known that the most likely 
source of most antimicrobial resistance is the use of antimicrobials in food-producing 
animals. 
The FDA also states that they not only need to be worried about animals 
becoming resistant to one specific pathogen, but that the process of how the bacteria is 
attacked might change the interaction of the bacteria in the animals intestine track.  
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“This therapy may also disturb the normal intestinal microbial ecosystem in the 
animal, resulting in an increase in the bacteria that can cause human infections or 
prolonging the duration of the carrier state of such bacteria (pathogen load). Animals 
carrying increased amounts of pathogens at the time of slaughter present an increased risk 
for contamination of food and resulting human illness. To keep this from potentially 
happening, the FDA currently requires applicants for over-the-counter uses of 
antimicrobials --------like those--------that will be administered as a feed additive for 
more than fourteen days--------- submit, as part of their safety data, the results of 
preapproval studies intended to detect the development of antimicrobial resistance in 
enteric bacteria from treated animals.” 5 
The five goals listed by the FDA for evaluating and maintaining safety are:  
“1) assessing the effect of proposed uses on human pathogen load; 
2) assessing the safety of proposed animal uses of drugs according to their (or 
related drugs) importance in human medicine and the potential human 
exposure to resistant bacteria acquired from food-producing animals that are 
human pathogens or that can transfer their resistance to human pathogens; 
3) assessing pre-approval data showing that the level of resistance transfer from 
proposed uses of drugs, if any, will be safe; 
4) establishing “resistance” and “monitoring” thresholds to ensure that approved 
uses do not result in resistance development in animals or transfer to humans 
above the established levels; and 
5) establishing post-approval studies and monitoring. 5 
 
 
 
8 
 
When assessing the resistance of bacteria from antimicrobial antibiotics that are 
used in livestock intended for human consumption, there are two important factors: 
1) The importance of the drug or drug class in human medicine 
2) The potential human exposure to resistant bacteria acquired from food-
producing animals that are human pathogens or that can transfer their 
resistance to human pathogens. 5 
These two factors lead to the FDA coming up with three categories for the 
antibiotics based on the importance of the drug or its use in human medicine, potential 
human exposure, and resistance to human pathogenic bacteria.  The FDA claims that by 
dividing the antimicrobial antibiotics into categories, it will be more efficient to learn 
more about them and to maintain long-term safety and stability. Table 2 (next page) 
describes the criteria for each category.  
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Table 2: Requirements to be in each category5 
Category I Category II Category III 
1) Essential for treatment of a serious or life 
threatening disease in humans (conditions of high 
morbidity or mortality) for which there is no 
satisfactory alternative therapy. 
2) Important for the treatment of foodborne 
diseases in humans where resistance to alternative 
antimicrobial drugs (e.g., Category II drugs) may 
limit therapeutic options (recognizing the special 
risks of both resistance development in, and 
transmission to, humans of foodborne pathogens). 
3) The drug is a member of a class of drugs for 
which the mechanism of action and/or the nature 
of resistance-induction is unique, resistance to the 
antimicrobial drug is rare among human 
pathogen(s), and the drug holds potential for long 
term therapy in human medicine. 
In addition, any antimicrobial that can induce or 
select for cross-resistance to a Category I drug 
would be considered a Category I drug. Similarly, 
if an antimicrobial is not used in human medicine, 
and if it could be demonstrated to the agency's 
satisfaction that it does not induce cross-
resistance to any antimicrobials in the same class 
used in human medicine that are Category I, then 
it would not be considered a Category I drug. 
The following are examples of types of drugs that 
would be included in Category I: 
1) Quinolones for serious infections caused by 
multi-drug resistant Salmonella spp. (resistant to 
Category II drugs). Quinolones are often the 
primary treatment for salmonellosis, which in the 
U.S. generally is food borne. Quinolones are also 
the drugs of choice and alternative therapies for 
many life-threatening resistant gram negative 
infections. 
2) Vancomycin for serious infections (e.g., sepsis, 
pneumonia, endocarditis) caused by methicillin 
resistant S. aureus, and ampicillin resistant 
enterococci. Vancomycin is the only well proven 
treatment drug available to treat serious infections 
with these organisms. 
3) Dalfopristin/quinupristin (Synercid) for 
vancomycin-resistant enterococcal infections. 
Additionally, Synercid has an unique mechanism 
of action. It was presented to an FDA Advisory 
Committee in February 1988. 
4) Third generation cephalosporins used to treat 
foodborne infections (e.g., ceftriaxone for 
Salmonellosis in children). 
 
1) Ampicillin for 
treatment of infections 
due to Listeria 
monocytogenes. The 
disease is life threatening; 
however, alternative 
therapies are available 
(e.g., trimethoprim-
sulfamethoxasole). 
2) Cephalosporins not in 
Category I which do not 
induce cross resistance to 
those in Category I; beta 
lactams and beta 
lactamase inhibitor 
combinations because 
they represent both drugs 
of choice and alternative 
therapies for many life 
threatening gram negative 
infections. 
3) Erythromycin for 
treatment 
of Campylobacter infectio
ns. 
4) Trimethoprim-
sulfamethosaxole for 
treatment of a wide range 
of serious enteric 
infections including 
susceptible Salmonella an
d Shigella infections. 
 
1) They have little or no 
use in human medicine. 
2) They are not the drug 
of first choice or a 
significant alternative for 
treating human infections 
including food borne 
infections. 
The following are 
examples of type of 
drugs that would be 
included in Category III: 
1) Ionophores (e.g., 
monensin) which 
currently have no usage 
in human medicine 
2) The polymixins (e.g., 
Polymixin B and 
colistin) since they have 
significant toxicities and 
have been supplanted by 
other drugs for virtually 
all human use. 
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The FDA started its evaluation of antimicrobial antibiotics with category I at the 
highest importance because of the high potential of resistance being developed in 
humans. They suggest obtaining threshold levels and then continuing to monitor these 
levels as the drugs may continue to change. The same suggestion is recommended for 
category II drugs though risk to humans is not as high.  Category III drugs are thought to 
be at a low risk of being harmful to humans at this time. These recommendations are for 
both traditional pharmaceuticals as well as agriculture. Monitoring of the farm is 
necessary to make sure that the guidelines are being followed, and that no excess 
pathogenic bacteria are being unintentionally released in the environment for human 
consumption.  
The FDA has clearly stated that more research needs to be conducted and 
standards set; however, the FDA is not the only group performing research at this time. 
As the FDA stated, their goals will take several years to achieve, but outside sources have 
been doing research on several factors of how humans are already being impacted with 
pathogenic bacteria. For example, there have been several studies on ground water runoff 
containing bacteria; there have also been studies on bacteria in soil. 
C. History of Tetracycline 
Tetracycline refers to a family of antibiotics with similar structures; the most 
common antibiotics in this family are shown in table 3.  
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Table 3: List of most common compounds in the tetracycline family.6  
Chemical Name Generic Name  Trade Name  Yr of 
discovery  
Status  Therapeutic 
administration 
7-Chlortetracycline Chlortetracycline Aureomycin 1948 Marketed  Oral  
5-Hydroxytetracycline Oxytetracycline Terramycin 1948 Marketed Oral and 
Parenteral  
Tetracycline Tetracycline Achromycin 1953 Marketed Oral  
6-Demethyl-7-
chlortetracycline 
Demethylchlortetracycline Declomycin 1957 Marketed Oral  
2-N-
Pyrrolidinomethyltetracycline 
Rolietracycline Reverin 1958 Marketed  Oral  
2-N-
Lysinomethyltetracycline 
Limecycline Tetralysal 1961 Marketed Oral and 
parenteral 
N-Methylol-7-
chlortetracycline 
Clomocycline Megaclor 1963 Marketed Oral  
6-Methylene-5-
hydroxytetracycline 
Methacycline Rondomycin 1965 Marketed Oral  
6-Deoxy-5-
hydroxytetracycline 
Doxycycline Vibramycin 1967 Marketed Oral and 
parenteral 
7-Dimethylamino-6-
demethyl-6-deoxytetracycline 
Minocycline Minocin 1972 Marketed Oral and 
parenteral  
9-(t-butylglycylamido)-
minocycline 
Tertiary-
butylglycylamidominocycline 
Tigilcycline 1993 Pahse II 
clinical 
trials  
 
 
TThree members of the tetracycline family that were of interest in this study were 
tetracycline, chlortetracycline, and oxytetracycline. The tetracycline family is known for 
having the same core structure with different function groups to make different forms of 
the family of tetracycline. The simplest form of the tetracycline family is 6-deoxy-6-
demethyltetracycline (Figure 1). 
 
Figure 1: The structure of 6-deoxy-6-demethyltetracycline6 
10 11
6
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 The basic structure shows the four fused rings labeled A, B, C, and D that 
compose the core of the tetracycline family. Specific zones of structural importance for 
antibacterial activity are “steriochemical configurations at 4a, 12a (A-B ring junction), 
and 4(dimethylamino group) positions, and conservation of the keto-eno system (position 
11, 12, and 12a) in proximity to the phenolic D ring.”6 The tetracycline structure is 
known for being affected by the chelation of metal ions at “the b-diketone system 
(positions 11 and 12) and the enol (positions 1 and 3) and carboxamide (position 2) 
groups of the A ring (20, 44).”6 
 The tetracyclines are a large family of similarly structured drugs. There are 
multiple pKa values for each one due to multiple functional groups that can be attached 
to core structure of the antibiotic.  Tetracycline has three pKa values:  3.3, 7.7, and 7.9 
the reason for these three different pKa values can be shown in figure 2 with the 
highlighted boxes. 
 
Figure 2: The structure of tetracycline7.  
OH
NH2
OOO OH
OH
HO
H
CH3 NH
H
OH
H3C CH3
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 The structure of chlortetracycline is shown below in figure 3. Chlortetracycline 
also has three pKa values:  3.3, 7.4, and 9.3.  
 
Figure 3: Structure of chlortetracycline.8 
Cl
OH OH O O
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O
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N
CH3H3C
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 The structure of oxytetracycline is shown below in figure 4. Oxytetracycline’s 
pKa values are 3.3, 3.7, and 9.1. 
 
Figure 4: Structure of oxytetracycline7.  
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 When looking for the tetracycline ions it is very important to note the parent ion 
and the precursor and product ion; this is because when setting the MS/MS parameters on 
the LCMS the product ion may provide a more defined peak than the precursor ion. Thus 
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being the values used to set the ions that are being looked for; these values can be seen in 
table 4. 
 
Table 4: Precursor and product ions.9 
Name Precursor Ion Product Ion 
Tetracycline 445 410, 427 
Oxytetracycline  461 426, 443 
Chlortetracycline  479 444, 462 
 
D. Proposed Research  
The research conducted addressed the issue of the swine containing antibiotics 
and then the waste being spread on fields or used in other forms that would cause an 
environmental impact that is harmful to humans. The research studied the levels of 
antibiotics in swine waste across the lifespan of the swine.  
 
II. EXPERIMENTAL 
A. Sampling Plan 
 The purpose of this project is to analyze swine waste for antibiotics across the 
time span of the swine production process. The chosen swine farm categorized the pigs 
into the following life span sections: gestation, farrowing, nursery, and finishing. 
Gestation is the stage were the female swine are impregnated. Farrowing is when the 
impregnated female swine give birth and the new baby swine stay with their mother for 
several days to a few weeks. Nursery is when the young swine are removed from their 
mother. Finishing is the last stage of growth and development before the swine are sent to 
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slaughter.  All samples were analyzed with LCMS after being processed with a solid 
phase extraction method.  
The samples were collected on the first day of each week from a swine facility in 
Curdsville, Kentucky for several weeks. Samples of approximately 250 mL each were 
collected from the gestation, farrowing, nursery, and finishing buildings. Most samples 
were collected using a meter-long plastic pipette with a large pipet bulb. Other samples 
were collected using a long pole with a plastic bottle attached to the end of it.  These 
sampling methods can be seen below in the pictures labeled figure 5 and figure 6. 
Samples were placed into 500-mL plastic bottles and transported to the USDA lab facility 
where they were split before being stored. The sample splits that were taken for LCMS 
analysis were stored in a refrigerated environment at four degrees Celsius to reduce 
degradation. 
    Figure 5: Sample Collection  
 
Figure 6: Sample Collection 
              
B. Sample Preparation and Solid Phase Extraction 
The samples were prepared by using a USDA Food Safety and Inspection 
Service, Office of Public Health Science method titled “Qualitative Identification of 
Tetracyclines.”10 This method was written to prepare liver, muscle and kidney samples of 
fish and poultry. Due to the solids and dirtiness of all the samples, this procedure was 
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thought to work for the waste samples. The samples were then processed with solid phase 
extraction to remove solids before injection into the LCMS. 
The samples were prepared for solid phase extraction by removing the majority of 
the solids via shaking and centrifuging the samples with a Mcllvaine/EDTA buffer The 
Mcllvaine/EDTA buffer was made by combining Mcllvaine buffer with sufficient 
disodium EDTA  dihydrate to give a 0.10 M EDTA concentration. Mcllvaine buffer is a 
mixture of 0.20 M dibasic sodium phosphate and 0.10 M citric acid in a 5:8 ratio whose 
pH is adjusted to 4.00±0.05.  
Ten mL of sample and 20 mL of Mcllvaine/EDTA buffer were added to a 50-mL 
centrifuge tube. This tube was then shaken for ten minutes at 450 revolutions per minute, 
and then centrifuged for 10 minutes at 2500 revolution per minute. Once the samples 
were centrifuged, the supernatant was poured off into a second centrifuge tube.  An 
additional 20 mL of Mcllvaine/EDTA buffer was added to the residue left in the bottom 
of the first centrifuge tube and the shaking and centrifuging repeated. After the second 
shaking and centrifuging was complete, the second supernatant was added to the first 
supernatant.  The supernatants were than centrifuged for 20 minutes at 4000 revolution 
per minute. The centrifuge tube was then stored 4°C until ready for further processing. 
The last step before solid phase extraction was filtration through a Büchner flask to 
remove any bugs or other debris left in the supernatant of the sample after the shake table 
and centrifuge steps. 
The solid phase extraction cartridges were placed onto a vacuum block apparatus 
so they would be under vacuum while performing the extraction, this is shown below in 
figure 7. 
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Figure 7: Picture of vacuum box used for solid phase extraction. 
 
 
The cartridges were conditioned with 10 mL of methanol followed by 20 mL of 
distilled water. The samples were then loaded onto the cartridge and washed with an 
additional 20 mL of distilled water. The cartridges were then allowed to dry under 
vacuum for two minutes. At this point the vacuum block would be filled with waste 
liquid that was removed before the sample was eluted from the cartridge.  Ten-mL 
transfer vials would be inserted to collect the sample as it was eluted from the cartridge.  
Once transfer vials were put in place to collect the eluted sample, 6 mL of 0.01 M 
methanolic oxalic acid solution were added to the cartridges to elute the sample. 
The samples that were collected were blown down to 0.5 mL with high purity 
Argon, using an evaporator instrument.  The sample was then brought back to 1 mL with 
methanol and 1 mL of LCMS grade water was added. The 2-mL sample was passed 
through a 0.2-μm syringe filter and into a 2-mL LCMS auto sampler vial. 
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All samples, including calibration curve samples, were processed in this fashion 
to make certain that loss on the cartridge was taken into account when calculating the 
concentration. A calibration curve was also run every day that samples were run.  
C. Liquid Chromatography Mass Spectroscopy Methods 
 Once the samples were prepared for the liquid chromatography mass spectrometer 
(LCMS) they were loaded into the auto sampler and run on the LCMS with the 
appropriate methods. The LCMS that was used for this research was an Agilent 500 ion 
trap LC/MS. With this specific instrument and the antibiotics that were being observed, it 
was not possible to run a MS/MS method that would be able to detect all three antibiotics 
properly. This is due to the retention times of the antibiotics being too close together. The 
instrument would need at least two minutes between retention times to properly switch 
the ion count. For this reason, three injections were necessary to analyze the three 
antibiotics.  
 For all three methods, the column, mobile phase, and pump settings were the 
same. The column was a Varian C18 100×2.0 mm column. The two mobile phases were 
LCMS grade acetonitrile and an ammonium acetate and trifluoroacetic acid (TFA) 
solution. The solution was 0.05 M ammonium acetate/0 
005 M TFA in LCMS grade water. These solutions were then mixed through the pumps 
with the ratios shown below along with the Gradient Method that was used; in table 5. 
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Table 5: Gradient Method 
Time (min:sec) Percent Ammonium 
Acetate Solution 
Percent Acetonitrile Flow (μL/min) 
0:00 90 10 225 
2:00 90 10 225 
2:06 50 50 225 
7:00 50 50 225 
7:06 90 10 225 
9:00 90 10 225 
The pump settings are the same for all three methods; however, for the MS/MS 
parameters the three antibiotics settings’ differ greatly and are listed below in table 6.  
These parameters were set based on the data that was obtained by optimizing all the 
antibiotic standards separately. 
When samples were injected into the LCMS it was very important to clean the 
LCMS due to the matrix of the samples that was being injected. The electron spray 
ionization (ESI) trap was cleaned with methanol daily; the ion trap was cleaned once a 
month following the directions provided by the manufacturer. 
T
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III. Results
The samples discussed here were run in two different batches, using two different LC 
MS systems.  The first batch was analyzed on the LCMS owned by Western Kentucky 
University between May 2013 and August 2013 and has the ion tag of 56. These samples 
are referred to and discussed as batch one. The second batch of samples was analyzed on 
a LCMS system owned by Agilent Technologies that was loaned to Western Kentucky 
University. These samples have an ion tag of 57 and were analyzed between January 
2014 and March 2014. These samples are referred to and discussed as batch two. The 
same HPLC methods were used on both systems; however, the MS ion tag recognition 
was different as noted above and a diverting method was added to batch two to eliminate 
the sample from entering the mass spectroscopy system during the full scanning time of 
the method. Instead, the sample was only entering the mass spectrometer during the 
window the antibiotic was eluting and being detected. 
A. Calibration Curves 
Calibration standards were analyzed each day samples were analyzed because the 
area count of the standards changed on a daily basis. These daily calibration curves were 
used to determine the concentrations of the samples across all four life cycles. Calibration 
standards were only analyzed for the specific antibiotic analyzed on that day. The 
calibration curves consisted of ten standards with known concentrations of 0.05, 0.075, 
0.10, 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, and 1.75 ppm. These standards were fit to a linear 
model, and the equation from the model was used to calculate the concentration of the 
swine samples.  Figure 8 shows a typical calibration curve that was used to determine the 
concentration of chlortetracycline on July 25th, which was a part of batch one.  
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Figure 8: Calibration curve example: July 25th Chlortetracycline Batch One 
 
 
 Scatter plots with linear fits for all batch 1 and batch 2 calibration curves are 
shown in succession below. Figures 9 and 10 show all of the chlortetracycline calibration 
curves for batch one and batch two, respectively.  Figures 11 and 12 show all of the 
tetracycline calibration curves batch one and batch two, respectively. Figure 13 shows all 
of the oxytetracycline calibration curves for batch one. 
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Figure 9: All calibration curves for batch one chlortetracycline. 
 
 
 
 
 
Figure 10: All calibration curves for batch two chlortetracycline.  
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Figure 11: All calibration curves for batch one tetracycline.  
 
 
Figure 12: All calibration curves for batch two tetracycline.  
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Figure 13: All calibration curves for batch one oxytetracycline 
 
 
B. Gestation  
Samples were analyzed in all batches for the gestation stage, tetracycline and 
chlortetracycline in batch one and batch two, and oxytetracycline in batch one. 
Concentrations are shown in bar graphs with their standard deviations as error bars for all 
samples. 
 
Figure 14 shows batch one oxytetracycline for the gestation stage. Detection of 
antibiotics was expected in this stage of life due to the swine becoming pregnant at this 
stage.  Swine would need to be in the top health to be able to conceive and have healthy 
off spring. The concentration of the antibiotic increased from the start of May through the 
end of August; there were a few weeks when the concentration dropped but the general 
trend was upward. The concentration varied from 0.62 to 3.02 ppm.  This was not the 
highest concentration of antibiotics across the lifespan of the swine, but it was the highest 
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concentration that was detected in the gestation phase. Tetracycline was detected, but not 
at the high levels found for oxytetracycline. 
 
Figure 14: Bar graph of gestation oxytetracycline batch one 
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 The gestation stage batch one tetracycline data are shown in figure 15. The 
highest tetracycline level that was detected was on the week of July 8th and it was just 
over 0.40 ppm. This was very surprising with the levels of the oxytetracycline that were 
present. What was even more surprising was the level of chlortetracycline that was 
detected. 
 
Figure 15: Bar graph of gestation tetracycline in batch one.  
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The gestation batch one chlortetracycline is shown in Figure 16.  
Chlortetracycline was only detected in two of the gestation batch one samples, both in the 
month of August and at just above 0.4 ppm. This indicated that chlortetracycline was not 
present in the moths that were surveyed. 
 
Figure 16: Bar graph of gestation chlortetracycline in batch one. 
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two are the LCMS system that was used and the LCMS diverting method being used.  
The samples that were prepared were stored in a deep freeze at -80°C in ultraviolet light 
protected boxes. These black boxes and the temperature level were chosen to help 
prevent light from degrading samples.  When the samples were run on the loaner 
instrument from Agilent Technologies (batch two), the results that were obtained were 
drastically different from batch one.  This is shown in figures 17 and 18.  
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Figure 17: Bar graph of gestation chlortetracycline in batch two. 
 
 
Figure 18: Bar graph of gestation tetracycline in batch two. 
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 Both the chlortetracycline and tetracycline concentrations from batch two are 
significantly higher than in batch one.  The chlortetracycline went from below detection 
limits approximately 3 ppm, with the higher concentrations in June and July, early in the 
gestation stage. The concentration dropped just below 0.50 ppm for August and 
September. This was still higher than the highest concentration of chlortetracycline found 
in batch one.  The tetracycline results were also higher, jumping from being below 1 ppm 
to above 10 ppm on average. 
 There are several reasons that this could have occurred, primarily they are the 
difference in instrument and the time. The difference in instrumentation was due to the 
first LCMS being contaminated by the samples.  This was suspected and confirmed by 
documented on a daily basis the ion count time both in full scan and in MS/MS scan on 
the loaner LCMS. The samples that were injected into the instrument were found to be 
contaminating the instrument. At some point during batch one, the instrument was 
contaminated, but the exact time is not known. This could have caused the low 
concentrations that were detected, and could explain the apparent absence of 
chlortetracycline from batch one that was then detected in batch two. 
 It should also be noted that the samples that were run in batch one and in batch 
two are the same samples. Unfortunately, it is not known how long samples can be stored 
without adversely affecting them. They were stored in deep freeze and in ultraviolent 
protected boxes to prevent degradation, but it is not knows what is adequate to fully 
protect the samples. 
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C. Farrowing 
Samples were analyzed in all batches for the farrowing stage, tetracycline and 
chlortetracycline in batch one and batch two, and oxytetracycline in batch one. Figure 19 
shows the oxytetracycline in the farrowing stage. The oxytetracycline was only slightly 
lower than it was in the gestation stage (figure 14) because at this stage the sows are 
giving birth and the piglets need to be as healthy as possible to be able to survive. 
 
Figure 19: Bar graph of farrowing oxytetracycline in batch one. 
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Tetracycline from farrowing batch one is shown in figure 20. The tetracycline in 
the farrowing stage is somewhat higher than in the gestation stage (figure 15). The 
gestation stage tetracycline peaks about 0.40 ppm and the farrowing stage peaks above 
1.0 ppm.  This may be due to the stage of life, as the piglets are preparing to leave their 
mother and be on their own in the nursery stage. When this occurs, they will no longer be 
able to get antibiotics through by nursing; instead, they will have to get it from other 
sources such as feed and water. 
 
Figure 20: Bar graph of farrowing tetracycline in batch one. 
 
 
 No chlortetracycline was detected in batch one; all the peaks were too small to 
quantify. Batch two has higher levels of tetracycline and shows levels of chlortetracycline 
that were not detectable in batch one. Tetracycline batch two and chlortetracycline batch 
two are shown in figures 21 and 22, respectively. 
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Figure 21: Bar graph of farrowing tetracycline in batch two.  
 
 
 The concentration of farrowing stage tetracycline was significantly higher in 
batch two than in batch one (figure 20). In batch one the highest was just above 1.0 ppm 
while the highest in batch two was over 12 ppm. The trends in both batch one and batch 
two are similar, though not identical. They both increase, but batch two is not as drastic 
as batch one (as a percentage of the maximum). The other difference is the samples from 
August and September were not analyzed in batch one.  They were analyzed in batch 
two, and they have high concentrations. 
 The farrowing chlortetracycline batch two was determined to be from 0.15 to 0.42 
ppm in contrast to batch one where all dates were below the detection limit. This can be 
attributed to the two different instruments and, perhaps, the storage of the samples 
between the days of the analyses. 
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Figure 22: Bar graph of farrowing chlortetracycline in batch two. 
 
 
D. Nursery 
Nursery is the stage in the life of a swine where very high levels of antibiotics 
were anticipated to be present due to the young swine being fully removed from their 
mothers. At this point, the young swine need to get their bacterial resistance from another 
source. It is likely that more antibiotics are added to the swine’s environment through 
their feed. Samples were analyzed in all batches for the nursery stage, tetracycline and 
chlortetracycline in batch one and batch two, and oxytetracycline in batch one. 
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Figure 23 shows the oxytetracycline in batch one for the nursery stage. This stage 
has the highest concentration of oxytetracycline. The levels vary from below 1 ppm to 
nearly 5 ppm, which is noticeably higher than the other stages of life as expected for this 
stage. 
 
Figure 23: Bar graph of nursery oxytetracycline in batch one. 
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The chlortetracycline results from batch one are shown in figure 24. The results 
for chlortetracycline in batch one are low and somewhat erratic, but that is consistent 
with the other batch one results for chlorotetracycline. 
 
Figure 24: Bar graph of nursery chlortetracycline in batch one.  
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Figure 25 shows the results for tetracycline in batch one. Nursery tetracycline 
batch one was very consistent and grew to a of 1.3 ppm.  The climb of the concentrations 
was very gradual and then dropped abruptly back to around 0.6 ppm. This was different 
than the oxytetracyline in batch one which climbed fell both more evenly.  However both 
the chlortetracycline and tetracycline in batch two do not match the results in batch one. 
 
Figure 25: Bar graph of nursery tetracycline in batch one.  
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Nursery chlortetracycline batch two and tetracycline batch two are shown in figures 26 
and 27, respectively. Chlortetracycline batch two is significantly higher than in batch one. 
The chlortetracycline not only increased, but on the days when there was none detected in 
batch one, it was found above 0.3 ppm in batch two. Tetracycline is also significantly 
higher in batch two than in batch one. 
 
Figure 26: Bar graph of nursery chlortetracycline in batch two.  
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Figure 27: Bar graph of nursery tetracycline in batch two.  
 
 
 Although the tetracycline and chlortetracycline from batch two do not match the 
trends from batch one for the nursery stage, they are the highest and most consistent 
levels in any stage. This was expected due to the swine being removed from their mothers 
and having acquired all their own resistance. 
E. Finishing 
The finishing stage was not expected to show any antibiotics or low levels of 
antibiotics. This is because in the finishing stage, the swine are completing growth and 
development before slaughter and the antibiotics should be out of their systems prior to 
slaughter.  Samples were analyzed in all batches for the finishing stage, tetracycline and 
chlortetracycline in batch one and batch two, and oxytetracycline in batch one. 
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Figure 28 shows the oxytetracycline in batch one for the finishing stage. Despite 
the hypothesis that the antibiotics would not be present in this stage, oxytetracycline was 
consistently present in low levels. There are sampling dates missing in this series due to 
the WKU LCMS failing before all of batch one could be analyzed. These samples are 
missing throughout the rest of batch one for the finishing stage. 
 
Figure 28: Bar graph of finishing oxytetracycline in batch one. 
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Tetracycline batch one for the finishing stage is shown in figure 29.  The low 
levels tetracycline found here follow the hypothesis that there should be no antibiotics or 
low levels of antibiotics present. They are all below 1 ppm of tetracycline. There were 
also no detectable levels of chlortetracycline in finishing batch one. 
 
Figure 29 Bar graph of finishing tetracycline in batch one.  
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 Finishing batch two for showed low levels of chlortetracycline as seen in figure 
30 where the chlortetracycline was present at first and then fell below detection limits. 
This followed the expected trend of low to undetectable antibiotics for the finishing stage. 
 
Figure 30: Bar graph of finishing chlortetracycline in batch two. 
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 However, this trend did not bear out for the tetracycline in the finishing stage as 
seen in figure 31. The tetracycline for batch two is very high, averaging above 10 ppm 
though the finishing stage. This is very surprising with finishing being the last stage 
before slaughter. 
 
Figure 31: Bar graph of finishing tetracycline in batch two.  
 
 
IV. Conclusion  
There were several discrepancies in the data that was collected from this study. 
The primary result is that there are antibiotics present at detectable levels in swine waste 
across the life span of the swine. This is important for the determination of amounts that 
are considered safe and appropriate for the production of swine.  
The life stage found to produce the most interesting results was the nursery stage 
because of it having the highest levels of antibiotics being detected out of every stage. 
They also have the most consistent levels across the dates sampled. The nursery section 
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needs to be extended not only to test waste but also the food, and water fed to the swine. 
This would give us insight into how much antibiotics are going into the animal and the 
concentration once it is processed and excreted through the animal.  
There were several factors that affected the results of this study and ultimately 
lead to the inconsistent results. The main causes are damage that was done to the WKU 
LCMS when injecting samples and then switching to the loaner LCMS from Agilent 
Technologies. 
Instrumentation failures compounded the problem by limiting the span of data 
collected. Conducting sampling and analysis over the course of at least nine months 
would give a better representation of trends. The current study has samples from late May 
to the beginning of September – only about four months. Investigating if the patterns 
repeat them across the lifespan of the swine could indicate that the result is not just from 
random treatments.  
Using two different instruments was a large factor in the differences between 
batch one and batch two across the sampling dates. Those large differences make it 
difficult to confirm the concentrations of antibiotics detected, leading the conclusion that 
antibiotics are present and detectable but the exact concentrations are not certain. 
The instrument became contaminated because of the samples used. Additional 
filtration or clean-up of the samples should be completed before injecting the samples 
into the instrument. The main objective would be to eliminate the yellow/brownish color 
that remains in the samples, the components of the sample that are giving the color are 
thought to be the contamination source.  Agilent Technologies staffs who were consulted 
on the instrument problems believe the source of the color of the sample is causing the 
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contamination. Agilent made several suggestions on what could be done to reduce the 
coloration of the samples. Most of these suggestions include a new method of extraction. 
One of the solid phase extractions currently being considered is a silica gel cartridge 
instead of the C18 cartridge used in this work. 
There are a few other directions in which this work could go.One option is to use 
ion exchange solid phase extraction to extract the antibiotics from the samples. This is a 
viable procedure because of the different ion charges in the tetracycline structure. . If 
using the current extraction method, fractional samples could be collected from the 
column in the time range the antibiotics are known to elute. Then those samples could be 
diluted and analyzed. This would allow the samples to not be injected into the ion trap for 
a longer period of time instead of having to use the diverting method for all times except 
when the antibiotic is known to elute. It might also be possible to use solid-phase micro-
extraction (SPME) for a more complete isolation of the antibiotics from the sample. 
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